Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33

Benzinga · 5d ago
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $30 to $33.